Dominant-negative p53 mutations in rheumatoid arthritis
- PMID: 10366100
- DOI: 10.1002/1529-0131(199906)42:6<1088::AID-ANR4>3.0.CO;2-E
Dominant-negative p53 mutations in rheumatoid arthritis
Abstract
Objective: Studies were performed to determine if p53 mutations identified in rheumatoid arthritis (RA) synovial tissue are dominant negative.
Methods: Site-directed mutagenesis was used to produce 2 RA-derived mutants: asparagine-->serine at codon 239 (N239S) and arginine-->stop at codon 213 R213*). HS68 dermal fibroblasts were transfected with either empty vector, wild-type p53 cDNA (wt), or the N239S or R213* mutant p53 cDNA clones. Interleukin-6 (IL-6) and bax gene expression were determined by Northern blot analysis. Bax transcription was determined using a bax promoter/reporter gene construct (bax-luc).
Results: Transfection of HS68 cells with wt increased bax mRNA levels. This process was blocked by cotransfection with either mutant. The mutant p53 genes also increased IL-6 gene expression. Low levels of bax promoter activity were detected in HS68 cells co-transfected with bax-luc and empty vector, N239S, or R213*, indicating that the RA mutants lacked transcriptional activity. Transfection with wt and bax-luc led to a 10-fold increase in luciferase expression. When the wt gene was cotransfected with either of the mutants, there was a dose-dependent inhibition of bax promoter activity.
Conclusion: These data indicate that at least 2 of the p53 mutants identified in RA joint samples are dominant negative and suppress endogenous wild-type p53 function.
Comment in
-
Absence of p53 mutation in Japanese patients with rheumatoid arthritis: comment on the article by Han et al.Arthritis Rheum. 2000 Feb;43(2):469-70. doi: 10.1002/1529-0131(200002)43:2<469::aid-anr34>3.0.co;2-d. Arthritis Rheum. 2000. PMID: 10693894 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
